$211 Million is the total value of Pivotal bioVenture Partners Investment Advisor LLC's 11 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2022 |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
KARUNA THERAPEUTICS INC | 12 | Q3 2023 | 65.4% |
VAXCYTE INC | 12 | Q3 2023 | 19.5% |
INOZYME PHARMA INC | 12 | Q3 2023 | 10.8% |
ARCUTIS BIOTHERAPEUTICS INC | 12 | Q3 2023 | 6.2% |
FUSION PHARMACEUTICALS INC | 12 | Q3 2023 | 6.2% |
ALIGOS THERAPEUTICS INC | 12 | Q3 2023 | 8.0% |
BOLT BIOTHERAPEUTICS INC | 11 | Q3 2023 | 20.0% |
RALLYBIO CORP | 9 | Q3 2023 | 14.1% |
AKOUOS INC | 8 | Q3 2022 | 11.7% |
EXSCIENTIA PLC | 8 | Q3 2023 | 6.4% |
View Pivotal bioVenture Partners Investment Advisor LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-14 |
13F-HR | 2024-02-13 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-12 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-10 |
13F-HR | 2022-08-12 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-14 |
View Pivotal bioVenture Partners Investment Advisor LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.